Chloroquine - Revision history

Ostermayer at 12:12, 20 March 2020

2020-03-20T12:12:03Z

← Older revision		Revision as of 12:12, 20 March 2020
Line 13:		Line 13:
	*Uncomplicated malaria treatment: 16.6 mg/kg PO (max 1 g), followed by 8.3 mg/kg PO at 6, 24, and 48 hours after first dose		*Uncomplicated malaria treatment: 16.6 mg/kg PO (max 1 g), followed by 8.3 mg/kg PO at 6, 24, and 48 hours after first dose
	*Malaria prophylaxis: 8.3 mg/kg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure		*Malaria prophylaxis: 8.3 mg/kg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure

			==Experimental Usage==
			*[[COVID-19]]

	==Special Populations==		==Special Populations==

ClaireLewis at 01:42, 20 September 2019

2019-09-20T01:42:28Z

← Older revision		Revision as of 01:42, 20 September 2019
Line 64:		Line 64:
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:ID]]

Fletc151: /* References */

2019-06-13T13:35:07Z

References

@@ Line 50: / Line 50: @@
 ==References==
 <references/>
 [[Category:Pharmacology]]

ClaireLewis: /* Adult Dosing */

2016-11-13T01:58:54Z

Adult Dosing

← Older revision		Revision as of 01:58, 13 November 2016
Line 6:		Line 6:

	==Adult Dosing==		==Adult Dosing==
	''Most malaria-endemic areas have high rates of chloroquine resistance. Per the CDC, chloroquine-sensitive areas include: Central America west of the Panama Canal, Haiti, the Dominican Republic, and most of the Middle East. See [[https://www.cdc.gov/malaria/travelers/country_table/a.html CDC malaria information by country]]''		''Most malaria-endemic areas have high rates of chloroquine resistance. Per the CDC, chloroquine-sensitive areas include: Central America west of the Panama Canal, Haiti, the Dominican Republic, and most of the Middle East. See [[https://www.cdc.gov/malaria/travelers/country_table/a.html CDC malaria information by country]] for details''
	*Uncomplicated malaria treatment: 1000 mg PO, followed by 500mg PO at 6, 24, and 48 hours after first dose		*Uncomplicated malaria treatment: 1000 mg PO, followed by 500mg PO at 6, 24, and 48 hours after first dose
	*Malaria prophylaxis: 500 mg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure		*Malaria prophylaxis: 500 mg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure

ClaireLewis: Created page with "==Administration== Type: Antimalarial Dosage Forms: Routes of Administration: Oral Common Trade Names: (Aralen) ==Adult Dosing== ''Most malaria-endemic areas have hig..."

2016-11-13T01:58:19Z

Created page with "==Administration== *Type: Antimalarial *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: (Aralen) ==Adult Dosing== ''Most malaria-endemic areas have hig..."

New page

==Administration==
*Type: [[Antimalarial]]
*Dosage Forms:
*Routes of Administration: Oral
*Common Trade Names: (Aralen)

==Adult Dosing==
''Most malaria-endemic areas have high rates of chloroquine resistance. Per the CDC, chloroquine-sensitive areas include: Central America west of the Panama Canal, Haiti, the Dominican Republic, and most of the Middle East. See [[https://www.cdc.gov/malaria/travelers/country_table/a.html CDC malaria information by country]]''
*Uncomplicated malaria treatment: 1000 mg PO, followed by 500mg PO at 6, 24, and 48 hours after first dose
*Malaria prophylaxis: 500 mg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure

==Pediatric Dosing==
*Uncomplicated malaria treatment: 16.6 mg/kg PO (max 1 g), followed by 8.3 mg/kg PO at 6, 24, and 48 hours after first dose
*Malaria prophylaxis: 8.3 mg/kg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C
*[[Lactation risk categories|Lactation risk]]: Infant risk minimal
*Renal dosing: reduce dose by 50% if CrCl < 10
*Hepatic dosing: may need serum drug level monitoring as 30-50% of dose modified by liver

==Contraindications==
*Allergy to class/drug
*Retinal or visual field changes

==Adverse Reactions==
===Serious===
*Prolonged QT, AV block
*Heart failure
*SJS
*Neutropenia
*Extrapyramidal disease
*Seizure
*Retinopathy
===Common===

==Pharmacology==
*Half-life: 1-2 months
*Metabolism: Hepatic
*Excretion: Renal, fecal

==Mechanism of Action==
*Precise mechanism unknown, action thought to be due to interaction with DNA

==Comments==

==See Also==
*[[Antimalarials]]
*[[Malaria]]

==References==
<references/>
[[Category:Pharmacology]]

Chloroquine - Revision history

Ostermayer at 12:12, 20 March 2020

ClaireLewis at 01:42, 20 September 2019

Fletc151: /* References */

ClaireLewis: /* Adult Dosing */

ClaireLewis: Created page with "==Administration== *Type: Antimalarial *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: (Aralen) ==Adult Dosing== ''Most malaria-endemic areas have hig..."

ClaireLewis: Created page with "==Administration== Type: Antimalarial Dosage Forms: Routes of Administration: Oral Common Trade Names: (Aralen) ==Adult Dosing== ''Most malaria-endemic areas have hig..."